Incidents of gastrointestinal (GI) cancers, such as oesophageal, gastric, and colorectal cancers, are increasing globally. In Hong Kong, these cancers are listed within the top ten. Although advancements in endoscopic submucosal dissection (ESD) have improved clinical outcomes, incomplete removal of cancer cells can lead to recurrence and untreated operation sites may also result in complications. The joint research project, between CUHK and CAS, aimed to develop a post-operative treatment for GI cancer using a medical micro-robotic platform. This innovative approach involved drug-loaded microrobots to deliver targeted therapy, covering operation sites to enhance healing and prevent cancer recurrence by eliminating residual cancer cells. The collaboration provided a diverse and complementary expertise in engineering and medicine, specialising in medical micro-/nano-robotics, minimally invasive surgery, and GI diseases.